AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 139 filers reported holding AERIE PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 2.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $289,000 | +4.0% | 19,147 | -48.3% | 0.00% | – |
| Q2 2022 | $278,000 | +81.7% | 37,025 | +120.5% | 0.00% | – |
| Q1 2022 | $153,000 | +30.8% | 16,794 | +0.9% | 0.00% | – |
| Q4 2021 | $117,000 | -38.4% | 16,645 | 0.0% | 0.00% | – |
| Q3 2021 | $190,000 | +50.8% | 16,645 | +111.9% | 0.00% | – |
| Q2 2021 | $126,000 | -5.3% | 7,855 | +5.4% | 0.00% | – |
| Q1 2021 | $133,000 | -47.4% | 7,451 | -60.3% | 0.00% | – |
| Q4 2020 | $253,000 | +15.0% | 18,747 | 0.0% | 0.00% | – |
| Q3 2020 | $220,000 | -27.4% | 18,747 | -8.7% | 0.00% | – |
| Q2 2020 | $303,000 | +6.3% | 20,544 | -2.6% | 0.00% | – |
| Q1 2020 | $285,000 | -48.8% | 21,085 | -8.5% | 0.00% | – |
| Q4 2019 | $557,000 | +35.9% | 23,044 | +8.0% | 0.00% | – |
| Q3 2019 | $410,000 | -29.6% | 21,330 | +8.3% | 0.00% | – |
| Q2 2019 | $582,000 | -30.9% | 19,702 | +11.1% | 0.00% | – |
| Q1 2019 | $842,000 | +32.6% | 17,739 | +0.8% | 0.00% | – |
| Q4 2018 | $635,000 | -12.3% | 17,592 | +49.5% | 0.00% | -100.0% |
| Q3 2018 | $724,000 | -10.4% | 11,764 | -1.6% | 0.00% | 0.0% |
| Q2 2018 | $808,000 | +19.7% | 11,956 | -4.0% | 0.00% | 0.0% |
| Q1 2018 | $675,000 | -22.6% | 12,448 | -14.2% | 0.00% | 0.0% |
| Q4 2017 | $872,000 | +35.4% | 14,512 | +9.6% | 0.00% | – |
| Q3 2017 | $644,000 | +62.6% | 13,245 | +75.8% | 0.00% | – |
| Q2 2017 | $396,000 | +24.1% | 7,534 | +7.4% | 0.00% | – |
| Q1 2017 | $319,000 | +16.8% | 7,015 | -2.9% | 0.00% | – |
| Q4 2016 | $273,000 | +59.6% | 7,221 | +60.1% | 0.00% | – |
| Q3 2016 | $171,000 | +151.5% | 4,509 | +17.5% | 0.00% | – |
| Q2 2016 | $68,000 | +44.7% | 3,836 | 0.0% | 0.00% | – |
| Q1 2016 | $47,000 | -42.0% | 3,836 | +13.7% | 0.00% | – |
| Q4 2015 | $81,000 | +37.3% | 3,375 | 0.0% | 0.00% | – |
| Q3 2015 | $59,000 | +55.3% | 3,375 | +53.5% | 0.00% | – |
| Q2 2015 | $38,000 | -44.9% | 2,199 | 0.0% | 0.00% | – |
| Q1 2015 | $69,000 | +6.2% | 2,199 | 0.0% | 0.00% | – |
| Q4 2014 | $65,000 | +44.4% | 2,199 | 0.0% | 0.00% | – |
| Q3 2014 | $45,000 | – | 2,199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |